 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Current Price	$1.41
Prev Close	$1.40
Open	$1.41
Dividend Yield	0.00%
50-Day Moving Average	$1.46
Beta	1.31
Avg. Volume	108,057.53
PE Ratio	-9.24

52-Week High	$2.37
52-Week Low	$1.15
Market Capitalization	$105.7M
EPS	-$0.1526
Price to Book	3.76
Revenue Per Employee	$684,486.73
Enterprise Value/EBITDA	-39.93

CDXC Chromadex Corp

About

Feed

Fundamentals

News